November is COPD Awareness Month and World COPD Day. Verona Pharma is raising awareness of this serious unmet need along with the American Lung Association and Asthma + Lung UK. Find out more about these support groups here
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Pulmonary Disease.Find out more
November 9 2022
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.